AARTI DRUGS LTD.
P&L
Quarterly Consolidated
vs Q2 FY25
Aarti Drugs Reports Q3 & 9M FY25 Financial Results: Revenue Down 6% & 10% YoY, PAT Stands at Rs. 37.1 Cr & Rs. 105.3 Cr
30 Jan 2025 · 30 Jan 2025, 02:39 am
Summary
Aarti Drugs Limited has reported its audited financial results for the quarter and nine months ending 31st December 2024. The company's consolidated revenue stood at Rs. 568.5 crores for Q3 FY25, a decline of 6% YoY, and Rs. 1,724.8 crores for 9M FY25, a decrease of 10% YoY. EBITDA for Q3 FY25 stood at Rs. 62.3 crores, a decline of 13% YoY, and Rs. 196.9 crores for 9M FY25, a decrease of 16% YoY. The company's PAT stood at Rs. 37.1 crores for Q3 FY25 and Rs. 105.3 crores for 9M FY25. The board has declared an interim dividend of Re. 1/- per equity share. The company is also acquiring 26.25% equity stake in a special purpose vehicle (SPV) for green energy needs.
Key Highlights
- 1
Revenue down 6% YoY for Q3 FY25 and 10% YoY for 9M FY25
- 2
EBITDA declines 13% YoY for Q3 FY25 and 16% YoY for 9M FY25
- 3
PAT stands at Rs. 37.1 crores for Q3 FY25 and Rs. 105.3 crores for 9M FY25
- 4
Interim dividend of Re. 1/- per equity share declared
- 5
Company is acquiring 26.25% equity shares of the Pro-Zeal Green Power Six Private Limited
Management Comments
Mr. Adhish Patil
CFO & COO, of Aarti Drugs Limited
This quarter has presented significant challenges for our API segment, with both revenue and profit declining on a year-on-year basis. This is mainly due to reduced market prices and weaker demand. Although prices remained stable during the December quarter, there was a negative price variance when compared to the same period last year. Formulation segment revenue stood at Rs. 48.6 crores for the quarter, with an export contribution of 47%. Despite facing these short-term challenges, we are staying focused on our long-term goals. We are confident about achieving double digit growth in revenues with EBITDA Margins of 13%-14% in FY26 which is a healthy indicator of our financial stability and operational efficiency.
Informational and educational content only. Not investment advice.